Breaking news: Despite promising hypotheses, the use of Dapagliflozin, a drug commonly prescribed for diabetes and heart failure, does not appear to reduce the recurrence of atrial fibrillation (AF) after catheter ablation — and this challenges some of our assumptions about its role. And here's where it gets controversial... But before jumping to conclusions, let's explore what this really means for patients and treatments.
The most recent findings from the DARE-HF trial, presented at the American Heart Association's 2025 Scientific Sessions, reveal that inhibiting sodium-glucose cotransporter 2 (SGLT2)—the mechanism targeted by dapagliflozin—does not help in lowering the frequency or burden of AF following ablation procedures. The study involved patients with persistent AF, who did not have other conditions like diabetes, heart failure, or kidney disease that would typically justify use of SGLT2 inhibitors.
Dr. Zixu Zhao from Beijing Anzhen Hospital shared that participants received dapagliflozin for three months post-ablation, yet their AF burden was statistically indistinguishable from those receiving usual care alone. The primary measure—AF burden over a week—was around 7.5% for the drug group and 8.1% for controls, with no significant difference (P = 0.48). Similarly, the rate of AF recurrence was nearly identical in both groups—about 29.5% versus 28%. Moreover, key indicators such as left atrial size and quality of life scores showed no meaningful improvement with dapagliflozin.
Safety-wise, the medication was well tolerated, with similar rates of serious adverse events in both groups. There were a couple of deaths in the dapagliflozin cohort—one due to a heart attack, another from cardiac arrest—but these were considered unrelated to the medication. Some side effects, including hypotension and urinary tract infections, were noted but were manageable.
This brings us to some important reflections. Many earlier studies, often involving patients with diabetes or heart failure, hinted at possible benefits of SGLT2 inhibitors for AF. These suggested that by improving underlying cardiac and metabolic health—like reducing obesity or managing hypertension—these drugs might indirectly influence the electrical stability of the heart. Yet, in patients without such comorbidities, as in this study, these effects seem absent.
Dr. Clyde Yancy from Northwestern emphasized that, based on the DARE-HF results, SGLT2 inhibition likely does not prevent AF recurrence in a broader, non-diabetic population following ablation. Instead, he advocates for well-established lifestyle modifications—like weight loss exceeding 10%, blood pressure management, sleep apnea treatment, and regular exercise—as proven strategies with tangible benefits. He highlights results from the ARREST-AF trial, which demonstrated that lifestyle interventions can significantly reduce AF burden.
But here’s where the debate heats up: Should we continue exploring pharmacological avenues like SGLT2 inhibitors for AF, or should we focus solely on holistic lifestyle factors that have proven benefits? Are we holding onto hope for a 'magic bullet' that may not exist? Share your thoughts below!
In summary, while dapagliflozin is a valuable medication for certain heart conditions, current evidence does not support its use solely to prevent AF recurrence post-ablation in patients without other indications. The core message remains: lifestyle modifications remain a cornerstone in managing and reducing AF risk—perhaps more reliably than experimental drugs at this stage.
